CHLA Clinical Research Studies

Having volunteers participate in research studies and clinical trials is critical to our research efforts. Thousands of children and families are involved in our patient-centered studies every year. Many of the treatments used today are based on the results of past research studies and clinical trials conducted with our patients. Our scientific and clinical experts take the best ideas from the laboratory -- to the patient -- in the form of promising new treatments.

By searching our study directory, you may identify research that could impact the life of your child or of another child you know. Because the number of available research studies and clinical trials for children nationwide is small, every participant makes a significant contribution.

In addition to enrolling children with certain diseases in order to study treatments and prevention of those diseases, we also need to study healthy children. Ask your child’s doctor about volunteer study options that may be suitable for your child.

Please contact the study staff listed in your search results for more information.

Search by Keyword:    

Back to the full listing

Study Details - ID: CHLA-17-00283
Health/Science/Disease Category:
CAH
Short Name:
Abiraterone Acetate in Children with Classic 21-Hydroxylase Deficiency
Full Title of Study:
A Phase 1-2 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children with Classic 21-Hydroxylase Deficiency
Phase/Type of Study:
Phase 1/2
Purpose of Research:
(1) determine the minimum effective dose of abiraterone acetate that normalizes androstenedione levels in prepubertal children with CAH secondary to 21-hydroxylase deficiency (Phase 1 trial), and (2) assess the utility of abiraterone acetate in prepubertal children with CAH as adjunctive therapy to minimize excessive androgen secretion and allow more physiological glucocorticoid replacement (Phase 2 trial).
Eligibility:
Males or females 2-9 years of age diagnosed with CAH
Time Commitment/Requirements:
Phase 1 - 6 Study Visits, Phase 2 -13 Study Visits
Primary Investigator:
Mitchell Geffner, MD
Coordinator Contact Name:
Norma Martinez
Phone Number:
323-361-5627
Email:
nzmartinez@chla.usc.edu
Clinical Trials .Gov Identifier:
NCT03548246